Literature DB >> 33103610

Stroke in COVID-19: A systematic review and meta-analysis.

Stefania Nannoni1, Rosa de Groot2, Steven Bell1, Hugh S Markus1.   

Abstract

BACKGROUND: Coronavirus disease 2019 (COVID-19) has become a global pandemic, affecting millions of people. However, the relationship between COVID-19 and acute cerebrovascular diseases is unclear. AIMS: We aimed to characterize the incidence, risk factors, clinical-radiological manifestations, and outcome of COVID-19-associated stroke.
METHODS: Three medical databases were systematically reviewed for published articles on acute cerebrovascular diseases in COVID-19 (December 2019-September 2020). The review protocol was previously registered (PROSPERO ID = CRD42020185476). Data were extracted from articles reporting ≥5 stroke cases in COVID-19. We complied with the PRISMA guidelines and used the Newcastle-Ottawa Scale to assess data quality. Data were pooled using a random-effect model. SUMMARY OF REVIEW: Of 2277 initially identified articles, 61 (2.7%) were entered in the meta-analysis. Out of 108,571 patients with COVID-19, acute CVD occurred in 1.4% (95%CI: 1.0-1.9). The most common manifestation was acute ischemic stroke (87.4%); intracerebral hemorrhage was less common (11.6%). Patients with COVID-19 developing acute cerebrovascular diseases, compared to those who did not, were older (pooled median difference = 4.8 years; 95%CI: 1.7-22.4), more likely to have hypertension (OR = 7.35; 95%CI: 1.94-27.87), diabetes mellitus (OR = 5.56; 95%CI: 3.34-9.24), coronary artery disease (OR = 3.12; 95%CI: 1.61-6.02), and severe infection (OR = 5.10; 95%CI: 2.72-9.54). Compared to individuals who experienced a stroke without the infection, patients with COVID-19 and stroke were younger (pooled median difference = -6.0 years; 95%CI: -12.3 to -1.4), had higher NIHSS (pooled median difference = 5; 95%CI: 3-9), higher frequency of large vessel occlusion (OR = 2.73; 95%CI: 1.63-4.57), and higher in-hospital mortality rate (OR = 5.21; 95%CI: 3.43-7.90).
CONCLUSIONS: Acute cerebrovascular diseases are not uncommon in patients with COVID-19, especially in those whom are severely infected and have pre-existing vascular risk factors. The pattern of large vessel occlusion and multi-territory infarcts suggests that cerebral thrombosis and/or thromboembolism could be possible causative pathways for the disease.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; Stroke; acute cerebrovascular disease; hemorrhagic stroke

Year:  2020        PMID: 33103610     DOI: 10.1177/1747493020972922

Source DB:  PubMed          Journal:  Int J Stroke        ISSN: 1747-4930            Impact factor:   5.266


  111 in total

1.  Advances in Acute Stroke Treatment 2020.

Authors:  Joseph P Broderick; Michael D Hill
Journal:  Stroke       Date:  2021-01-20       Impact factor: 7.914

2.  What the Aftermath of the Global Pandemic Will Mean for Neurologists.

Authors:  Stela Rutovic; Ekaterina Volevach; Hana Maršálková; Ana Isabel Fumagalli; Francesco Corea
Journal:  Neurol Int       Date:  2021-07-09

3.  COVID-19 and Risk of Acute Ischemic Stroke Among Medicare Beneficiaries Aged 65 Years or Older: Self-Controlled Case Series Study.

Authors:  Quanhe Yang; Xin Tong; Mary G George; Anping Chang; Robert K Merritt
Journal:  Neurology       Date:  2022-02-03       Impact factor: 9.910

Review 4.  Treating the body to prevent brain injury: lessons learned from the coronavirus disease 2019 pandemic.

Authors:  Tracey H Fan; Veronika Solnicky; Sung-Min Cho
Journal:  Curr Opin Crit Care       Date:  2022-04-01       Impact factor: 3.687

5.  Thromboembolic Risk in Hospitalized and Nonhospitalized COVID-19 Patients: A Self-Controlled Case Series Analysis of a Nationwide Cohort.

Authors:  Frederick K Ho; Kenneth K C Man; Mark Toshner; Colin Church; Carlos Celis-Morales; Ian C K Wong; Colin Berry; Naveed Sattar; Jill P Pell
Journal:  Mayo Clin Proc       Date:  2021-07-16       Impact factor: 7.616

6.  COVID-19 vaccines and vaccine hesitancy: Role of the allergist/immunologist in promotion of vaccine acceptance.

Authors:  Joseph A Bellanti
Journal:  Allergy Asthma Proc       Date:  2021-08-09       Impact factor: 2.587

Review 7.  Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of postacute COVID-19 syndrome.

Authors:  Anthony L Komaroff; W Ian Lipkin
Journal:  Trends Mol Med       Date:  2021-06-07       Impact factor: 11.951

8.  Neurologic Injury in Patients With COVID-19 Who Receive VV-ECMO Therapy: A Cohort Study.

Authors:  Nivedha V Kannapadi; Meghana Jami; Lavienraj Premraj; Eric W Etchill; Katherine Giuliano; Errol L Bush; Bo Soo Kim; Stella Seal; Glenn Whitman; Sung-Min Cho
Journal:  J Cardiothorac Vasc Anesth       Date:  2021-05-13       Impact factor: 2.628

Review 9.  Cardio-Pulmonary Sequelae in Recovered COVID-19 Patients: Considerations for Primary Care.

Authors:  Zouina Sarfraz; Azza Sarfraz; Alanna Barrios; Radhika Garimella; Asimina Dominari; Manish Kc; Krunal Pandav; Juan C Pantoja; Varadha Retnakumar; Ivan Cherrez-Ojeda
Journal:  J Prim Care Community Health       Date:  2021 Jan-Dec

10.  Ischemic Stroke: An Underestimated Complication of COVID-19.

Authors:  Wen Cao; Cong Zhang; Huan Wang; Qianqian Wu; Yujia Yuan; Junmin Chen; Shuo Geng; Xiangjian Zhang
Journal:  Aging Dis       Date:  2021-06-01       Impact factor: 6.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.